Sonoma Pharmaceuticals, Inc. (SNOA)
Oxford Ledge is still expanding full research coverage of SNOA. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Sonoma Pharmaceuticals is a global developer and producer of stabilized hypochlorous acid products for healthcare applications, sold through distribution partners in over 55 countries.
Source: 10-K (2026-03-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-18
- 10-K Annual financial report with audited statements 2026-06-16
- DEF 14A Proxy statement for shareholder vote 2026-05-05
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-04-30
- S-1/A Amended registration statement 2026-04-23
Source: SEC EDGAR.
Annual results
5 years of annual figures for SNOA, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2026 | $19.5M | -$3.2M | -$1.89 |
| 2025 | $14.3M | -$3.5M | -$2.79 |
| 2024 | $12.7M | -$4.8M | -$10.63 |
| 2023 | $13.3M | -$5.2M | -$1.52 |
| 2022 | $12.6M | -$5.1M | -$1.92 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for SNOA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SNOA in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.